Free Research Reports on These Healthcare Stocks -- Sanofi, DURECT, Sucampo Pharma, and Perrigo

Tuesday, November 28, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 28, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information has issued free tailored Stock Review on SNY, DRRX, SCMP, and PRGO which is a click away at Charles Schwab reported that, in general, Healthcare
companies' balance sheets are solid, their stocks have offered attractive dividend yields, and the sector's overall cost structure appears to have improved. Demand appears to be on the rise for health care products and services. Today, reviews Sanofi (NYSE: SNY), DURECT Corp. (NASDAQ: DRRX), Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP), and Perrigo Co. PLC (NYSE: PRGO). Free Downloads on Wall St. Equities today, sign up now and access these stocks' research reports at:


Paris, France headquartered Sanofi's stock finished Monday's session 1.06% lower at $45.61. A total volume of 1.21 million shares was traded, which was above their three months average volume of 1.16 million shares. The Company's shares have gained 12.78% since the start of this year. The stock is trading below its 200-day moving average by 3.44%. Moreover, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic solutions, have a Relative Strength Index (RSI) of 43.62.

On November 02nd, 2017 at the 1st European ATTR Amyloidosis Meeting for Patients and Doctors in Paris, Sanofi Genzyme, a business unit of Sanofi, and Alnylam Pharmaceuticals, Inc. (ALNY) announced positive complete results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy. Based on these results, ALNY intends to file a new drug application in the US for patisiran by end-2017 and a marketing authorization application in the European Union shortly thereafter.

On November 15th, 2017, research firm Barclays upgraded the Company's stock rating from 'Underweight' to 'Equal Weight'. Free Access to this morning's research report on SNY at:


Shares in Cupertino, California headquartered DURECT Corp. declined 0.89%, ending yesterday's session at $1.11 with a total trading volume of 603,470 shares. The stock has surged 42.36% in the past month. The Company's shares are trading 15.31% below their 200-day moving average. Moreover, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, has an RSI of 50.86.  

On November 01st, 2017, DURECT announced its results for the three months ended September 30th, 2017. Total revenues were $20.7 million and net income was $6.1 million for Q3 2017, as compared to total revenues of $3.7 million and net loss of $8.8 million for Q3 2016. At September 30th, 2017, cash and investments were $41.8 million, compared to cash and investments of $25.2 million at December 31st, 2016. Find your free research report DRRX at:

Sucampo Pharmaceuticals 

On Monday, Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc.'s stock climbed 0.95%, to close the day at $10.65. A total volume of 529,130 shares was traded, which was above their three months average volume of 492,570 shares. The Company's shares have advanced 10.36% in the last one month. The stock is trading 0.15% below its 50-day moving average. Additionally, shares of Sucampo Pharma, which focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the US, Japan, Switzerland, and internationally, have an RSI of 53.44.  

On November 14th, 2017, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $14 per share.

On November 21st, 2017, Sucampo Pharma announced that it will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017, at 11:30 a.m. ET. The fireside chat will be webcast live and may be accessed under the Event Calendar page of the Company's website. Sign up today for the free research report on SCMP at:


Shares in Dublin, Ireland headquartered Perrigo Co. PLC ended the day 0.59% lower at $86.06. A total volume of 859,354 shares was traded. The stock has gained 3.02% in the last one month, 9.81% in the previous three months, and 3.40% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 0.54% and 12.04%, respectively. Furthermore, shares of Perrigo, which together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide, have an RSI of 53.54.  

On November 02nd, 2017, Perrigo announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on December 19th, 2017, to shareholders of record on December 01st, 2017.

On November 10th, 2017, research firm RBC Capital Markets upgraded the Company's stock rating from 'Underperform' to 'Sector Perform' while revising its previous target price from $64 a share to $86 a share. Wall St. Equities' research coverage also includes the downloadable free report on PRGO at:


Wall St. Equities: 

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store